|Also gives||Pharmaceutical Third Party Manufacturing|
It is potent, long ecting inhibitor with high selectivity for DPP-4
It shows improved glycemic control in patients with type 2 diabetes
It provides a valuable treatment option for individuals with inadequate glycaemic control despite ongoing combination therapy with metformin and sulphonylurea
Increases insulin sensitivity, improves peripheral uptake of glucose and reduces hepatic glucose output
Reduces blood glucose level without weight gain and has minimal risk of hypoglycemia
PATIENTS WITH TYPE 2 DIABETES,
ADDING LINAGLIPTIN TO METFORMIN SIGNIFICANTLY IMPROVES GLYCAEMIC CONTROL AND WELL TOLERATED.
Better efficacy due to better regulation of the glucose homeostasis. Better Safety due to low propensity for hypoglycaemia.
Better tolerance due to
pharmacokinetics and pharmacodynamics relevancy